BACKGROUND: Circulating biomarkers can offer insight into subclinical cardiovascular stress and thus have the potential to aid in risk stratification and tailoring of therapy. METHODS AND RESULTS: We measured plasma levels of 4 cardiovascular biomarkers, midregional pro-atrial natriuretic peptide (MR-proANP), midregional pro-adrenomedullin (MR-proADM), C-terminalpro-endothelin-1 (CT-proET-1), and copeptin, in 3717 patients with stable coronary artery disease and preserved left ventricular ejection fraction who were randomized totrandolapril or placebo as part of the Prevention of Events With Angiotensin Converting Enzyme (PEACE) trial. After adjustment for clinical cardiovascular risk predictors and left ventricular ejection fraction, elevated levels of MR-proANP, MR-proADM, and CT-proET-1 were independently associated with the risk of cardiovascular death or heart failure (hazard ratios per 1-SD increase in log-transformed biomarker levels of 1.97, 1.48, and 1.47, respectively; P≤0.002 for each biomarker). These 3 biomarkers also significantly improved metrics of discrimination when added to a clinical model. Trandolapril significantly reduced the risk of cardiovascular death or heart failure in patients who had elevated levels of ≥2 biomarkers (hazard ratio, 0.53; 95% confidence interval, 0.36-0.80), whereas there was no benefit in patients with elevated levels of 0 or 1 biomarker (hazard ratio, 1.09; 95% confidence interval, 0.74-1.59; P(interaction)=0.012). CONCLUSIONS: In patients with stable coronary artery disease and preserved left ventricular ejection fraction, our results suggest that elevated levels of novel biomarkers of cardiovascular stress may help identify patients who are at higher risk of cardiovascular death and heart failure and may be useful to select patients who derive significant benefit from angiotensin-converting enzyme inhibitor therapy.
RCT Entities:
BACKGROUND: Circulating biomarkers can offer insight into subclinical cardiovascular stress and thus have the potential to aid in risk stratification and tailoring of therapy. METHODS AND RESULTS: We measured plasma levels of 4 cardiovascular biomarkers, midregional pro-atrial natriuretic peptide (MR-proANP), midregional pro-adrenomedullin (MR-proADM), C-terminal pro-endothelin-1 (CT-proET-1), and copeptin, in 3717 patients with stable coronary artery disease and preserved left ventricular ejection fraction who were randomized to trandolapril or placebo as part of the Prevention of Events With Angiotensin Converting Enzyme (PEACE) trial. After adjustment for clinical cardiovascular risk predictors and left ventricular ejection fraction, elevated levels of MR-proANP, MR-proADM, and CT-proET-1 were independently associated with the risk of cardiovascular death or heart failure (hazard ratios per 1-SD increase in log-transformed biomarker levels of 1.97, 1.48, and 1.47, respectively; P≤0.002 for each biomarker). These 3 biomarkers also significantly improved metrics of discrimination when added to a clinical model. Trandolapril significantly reduced the risk of cardiovascular death or heart failure in patients who had elevated levels of ≥2 biomarkers (hazard ratio, 0.53; 95% confidence interval, 0.36-0.80), whereas there was no benefit in patients with elevated levels of 0 or 1 biomarker (hazard ratio, 1.09; 95% confidence interval, 0.74-1.59; P(interaction)=0.012). CONCLUSIONS: In patients with stable coronary artery disease and preserved left ventricular ejection fraction, our results suggest that elevated levels of novel biomarkers of cardiovascular stress may help identify patients who are at higher risk of cardiovascular death and heart failure and may be useful to select patients who derive significant benefit from angiotensin-converting enzyme inhibitor therapy.
Authors: Stephan von Haehling; Gerasimos S Filippatos; Jana Papassotiriou; Mariantonietta Cicoira; Ewa A Jankowska; Wolfram Doehner; Piotr Rozentryt; Corrado Vassanelli; Joachim Struck; Waldemar Banasiak; Piotr Ponikowski; Dimitrios Kremastinos; Andreas Bergmann; Nils G Morgenthaler; Stefan D Anker Journal: Eur J Heart Fail Date: 2010-03-09 Impact factor: 15.534
Authors: Marc S Sabatine; David A Morrow; Kathleen A Jablonski; Madeline Murguia Rice; J Wayne Warnica; Michael J Domanski; Judith Hsia; Bernard J Gersh; Nader Rifai; Paul M Ridker; Marc A Pfeffer; Eugene Braunwald Journal: Circulation Date: 2007-03-19 Impact factor: 29.690
Authors: Renate B Schnabel; Andreas Schulz; C Martina Messow; Edith Lubos; Philipp S Wild; Tanja Zeller; Christoph R Sinning; Hans J Rupprecht; Christoph Bickel; Dirk Peetz; François Cambien; Tibor Kempf; Kai C Wollert; Emelia J Benjamin; Karl J Lackner; Thomas F Münzel; Laurence Tiret; Ramachandran S Vasan; Stefan Blankenberg Journal: Eur Heart J Date: 2010-09-18 Impact factor: 29.983
Authors: Torbjørn Omland; James A de Lemos; Marc S Sabatine; Costas A Christophi; Madeline Murguia Rice; Kathleen A Jablonski; Solve Tjora; Michael J Domanski; Bernard J Gersh; Jean L Rouleau; Marc A Pfeffer; Eugene Braunwald Journal: N Engl J Med Date: 2009-11-25 Impact factor: 91.245
Authors: Deddo Moertl; Rudolf Berger; Joachim Struck; Andreas Gleiss; Alexandra Hammer; Nils G Morgenthaler; Andreas Bergmann; Martin Huelsmann; Richard Pacher Journal: J Am Coll Cardiol Date: 2009-05-12 Impact factor: 24.094
Authors: Björn Zethelius; Lars Berglund; Johan Sundström; Erik Ingelsson; Samar Basu; Anders Larsson; Per Venge; Johan Arnlöv Journal: N Engl J Med Date: 2008-05-15 Impact factor: 91.245
Authors: Torbjørn Omland; Marc S Sabatine; Kathleen A Jablonski; Madeline Murguia Rice; Judith Hsia; Ragnhild Wergeland; Sverre Landaas; Jean L Rouleau; Michael J Domanski; Christian Hall; Marc A Pfeffer; Eugene Braunwald Journal: J Am Coll Cardiol Date: 2007-06-29 Impact factor: 24.094
Authors: Vikas Kumar; Timothy Dean Calamaras; Dagmar Haeussler; Wilson Steven Colucci; Richard Alan Cohen; Mark Errol McComb; David Pimentel; Markus Michael Bachschmid Journal: Antioxid Redox Signal Date: 2012-08-10 Impact factor: 8.401
Authors: Navaid Iqbal; Bailey Wentworth; Rajiv Choudhary; Alejandro De La Parra Landa; Benjamin Kipper; Arrash Fard; Alan S Maisel Journal: Cardiovasc Diagn Ther Date: 2012-06
Authors: Viviany R Taqueti; Leslee J Shaw; Nancy R Cook; Venkatesh L Murthy; Nishant R Shah; Courtney R Foster; Jon Hainer; Ron Blankstein; Sharmila Dorbala; Marcelo F Di Carli Journal: Circulation Date: 2016-11-14 Impact factor: 29.690
Authors: Brian A Bergmark; Jacob A Udell; David A Morrow; Petr Jarolim; Julia F Kuder; Scott D Solomon; Marc A Pfeffer; Eugene Braunwald; Marc S Sabatine Journal: Eur J Heart Fail Date: 2019-02-18 Impact factor: 15.534